Germany · Delayed Price · Currency is EUR Cereno Scientific AB Company Description
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden and internationally.
The company’s lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and anti-thrombotic properties.
Its drugs portfolio includes CS014, an epigenetic modulator that is in phase I for the treatment of cardiovascular, pulmonary diseases, and idiopathic pulmonary fibrosis; and preclinical drug candidates comprises CS585, a selective prostacyclin (IP) receptor agonist for the treatment of rare thrombotic diseases, such as anti phospholipid syndrome.
The company has a collaboration agreement with the University of Michigan for the preclinical development program of CS585 and CS014, are preclinical drug candidate for cardiovascular diseases; and Abbott for use of CardioMEMS HF System.
Cereno Scientific AB (publ) was incorporated in 2012 and is headquartered in Gothenburg, Sweden.
| Country | Sweden |
| Founded | 2012 |
| Industry | Pharmaceutical Preparations |
| Employees | 10 |
| CEO | Sten Sorensen |
Contact Details
Address: Förändringens gata 10 Gothenburg, 431 53 Sweden | |
| Phone | 46 768 66 77 87 |
| Website | cerenoscientific.com |
Stock Details
| Ticker Symbol | 4A1 |
| Exchange | Frankfurt Stock Exchange |
| Share Class | Class B Shares |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sten Sorensen | Chief Executive Officer |
| Eva Jagenheim | Chief Financial Officer |
| Tove Bergenholt | Head of Investor Relations |